



Antimycobacterial activity of peptide conjugate of pyridopyrimidine derivative against *Mycobacterium tuberculosis* in a series of *in vitro* and *in vivo* models

Kata Horváti^a, Bernadett Bacsa^a, Nóra Szabó^b, Kinga Fodor^c, Gyula Balka^d, Miklós Rusvai^d, Éva Kiss^e, Gábor Mező^a, Vince Grolmusz^f, Beáta Vértessy^g, Ferenc Hudecz^{a, h}, Szilvia Bösze^{a, *}

^a MTA-ELTE Research Group of Peptide Chemistry, Hungarian Academy of Sciences, Eötvös L. University, Budapest, Hungary

^b Laboratory of Bacteriology, Korányi National Institute for Tuberculosis and Respiratory Medicine, Budapest, Hungary

^c Department of State Veterinary Medicine and Agricultural Economics, Faculty of Veterinary Science, Szent István University, Budapest, Hungary

^d Department of Pathology and Forensic Veterinary Medicine, Faculty of Veterinary Science, Szent István University, Budapest, Hungary

^e Laboratory of Interfaces and Nanostructures, Eötvös L. University, Budapest, Hungary

^f Protein Information Technology Group, Eötvös L. University, Budapest, Hungary

^g Institute of Enzymology, Hungarian Academy of Science, Budapest, Hungary

^h Department of Organic Chemistry, Eötvös L. University, Budapest, Hungary

S U M M A R Y

Keywords:

In silico docking
Pyridopyrimidines
Peptide conjugate
PLGA encapsulation
Guinea pig infection model

New pyridopyrimidine derivatives were defined using a novel HTS *in silico* docking method (FRIGATE). The target protein was a dUTPase enzyme (EC 3.6.1.23; Rv2697) which plays a key role in nucleotide biosynthesis of *Mycobacterium tuberculosis* (*Mtb*). Top hit molecules were assayed *in vitro* for their antimycobacterial effect on *Mtb* H₃₇Rv culture. In order to enhance the cellular uptake rate, the TB820 compound was conjugated to a peptid-based carrier and a nanoparticle type delivery system (poly(lactide-co-glycolide), PLGA) was applied. The conjugate had relevance to *in vitro* antitubercular activity with low *in vitro* and *in vivo* toxicity. In a *Mtb* H₃₇Rv infected guinea pig model the *in vivo* efficacy of orally administrated PLGA encapsulated compound was proven: animals maintained a constant weight gain and no external clinical signs of tuberculosis were observed. All tissue homogenates from lung, liver and kidney were found negative for *Mtb*, and diagnostic autopsy showed that no significant malformations on the tissues occurred.

© 2015 Elsevier Ltd. All rights reserved.

1. Introduction

In silico docking methods and structure-based drug design are useful bioinformatics tools for identifying new agents against tuberculosis. In our previous study [1], a newly developed FRIGATE docking algorithm [2] was utilized for a virtual screen of several million small molecules against the species-specific surface loop of *Mtb* DUTPase (EC 3.6.1.23; Rv2697) enzyme [3,4]. As a result, we reported the identification of 10 new compounds, active against *Mtb* H₃₇Rv *in vitro*. The lowest minimal inhibitory concentration

(MIC) was measured for TB8 compound (1 µg/mL, 3.7 µM), a pyridopyrimidine derivative. To optimize the structure of TB8 compound, more than 100 derivatives were synthesized, *in vitro* evaluated and the structure-activity relationship was analyzed. One of the derivatives, TB820 molecule (4-oxo-2-(pyrrolidin-1-yl)-pyrido[1,2-a]pyrimidine-3-carbaldehyde) was chosen in this study for further modification in order to improve its therapeutic efficacy by using advanced drug delivery system (DDS).

Targeted delivery of antitubercular drugs into macrophages, which provide the intracellular survival of the mycobacteria, has crucial pharmaceutical benefits. The phagocytic uptake process of macrophages is highly efficient due to the expression of specific receptors such as the IgG receptor and complement receptors [5]. DDS can be engineered to achieve enhanced cellular uptake and bioavailability, controlled drug release and reduced side effects. In

* Corresponding author. MTA-ELTE Research Group of Peptide Chemistry, Pázmány P. stny. 1/A, Budapest, 1117, Hungary. Tel.: +36 1 372 2500x1736; fax: +36 1 372 2620.

E-mail address: szilvia.bosze@gmail.com (S. Bösze).

this paper we report the design of a new type of advanced DDS, where the antitubercular agent is conjugated to a tuftsin peptide derivative and encapsulated into PLGA nanoparticles. Tuftsin is a natural phagocytosis stimulating peptide produced by enzymatic cleavage of the Fc-domain of the heavy chain of IgG. During the past decade, a new group of sequential oligopeptide carriers has been developed in our laboratory: oligotuftsins derivatives consisting of a pentapeptide unit TKPKG [6,7]. In this study, the TKPKG peptide was elongated with palmitic acid to enhance the lipophilicity, membrane affinity and encapsulation efficacy. Nanoencapsulation into lactic and glycolic acid (PLGA) copolymers is an efficient method for sustained controlled release and intensively explored for antitubercular therapy [8]. These biodegradable and biocompatible polymer-based nanoparticles have the ability to essentially modify the biodistribution of an active compound and the release rate can be controlled by the size and composition of the particles [9]. PLGA is approved by the US Food and Drug Administration (FDA) for clinical use and it can be utilized in oral formulation [10].

Synthesis and characteristics of peptide-conjugated and PLGA encapsulated TB820 is described in this work. *In vitro* antitubercular efficacy of the conjugate is compared to its cytotoxicity and hemolytic activity. Furthermore, *in vivo* chemotherapeutic effect of the orally administered PLGA-pT820 compound in a guinea pig infectious model is presented.

2. Materials and methods

2.1. Synthesis and characterization of PLGA encapsulated pal-T5(TB820)₂

The TB820 compound was provided by Ubichem Pharma Services (Budapest, Hungary) and conjugated to a palmitoylated tuftsin derivative. First protected tuftsin (TKPKG, T5) was produced manually by solid-phase peptide synthesis using Boc/Bzl strategy. Palmitic acid was coupled to the N-terminus of the peptide. The N²-Fmoc protecting groups of the side chain of Lys residues were selectively removed and free amino groups were reacted with Boc-aminooxyacetic acid. After Boc deprotection, peptide was removed from the resin with liquid HF in the presence of scavengers. Palmitoylated aminooxy-peptide was then allowed to react with the TB820 compound in solution and the precipitated conjugate was filtered and purified. Final product pal-T5(TB820)₂ (pT820) was characterized by analytical RP-HPLC, ESI-MS and amino acid analysis.

PLGA nanoparticles were prepared by the nanoprecipitation (solvent exchange) method, detailed previously [11,12]. Briefly, PLGA and pT820 conjugate were dissolved in acetone and added dropwise to an aqueous solution of Pluronic 12700. The resulting nanoparticle suspension was centrifuged, purified by dialysis and freeze-dried. Drug content of the lyophilized powder was determined by amino acid analysis.

2.2. *In vitro* tests

In vitro antitubercular activity of the compound was determined against *Mycobacterium tuberculosis* H₃₇Rv (ATCC 27294) and multi-resistant *M. tuberculosis* (MDR A8) by serial dilution method in Sula semi-synthetic medium. The minimal inhibitory concentration (MIC) was determined after incubation at 37 °C for 28 days. The activity of the tested compounds was confirmed using colony forming unit (CFU) enumeration by subculturing from the Sula medium onto drug-free Löwenstein-Jensen solid medium (37 °C, 28 days).

In vitro cytotoxicity was evaluated on human peripheral blood mononuclear cells (PBMC), prepared from peripheral blood of healthy volunteers using Ficoll-Hypaque density gradient centrifugation method. The pT820 conjugate was added to the cells

to give 0.5 μM–200 μM final concentrations. Cells were incubated at 37 °C for 4 h, then cell viability was tested using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay.

In vitro hemolytic activity of pT820 was determined on human erythrocytes. Red blood cell suspension was incubated with the compounds (0.5 μM–200 μM final concentrations) for 4 h at 37 °C and after centrifugation, the absorbance of the supernatant was measured at λ=450 nm.

2.3. *In vivo* evaluation

Inbred, female guinea pigs aged 6 weeks at weight 400–500 g were housed four per cage and allowed free access to water and to standard pellet diet. All animal experiments were approved by the Hungarian Scientific Ethical Committee on Animal Experimentation (No: 22.1/3720/003/2009).

To study the *in vivo* toxicity, animals were administered orally twice a week with 50 mg/kg bw of PLGA-pT820 (n = 3 for the treatment group). To monitor the side effects, changes in body weight were determined weekly and after 7 weeks of administration, animals were euthanized and diagnostic autopsy was evaluated.

In vivo antitubercular effect of the PLGA-pT820 compound was evaluated on *Mtb* infected guinea pigs (n = 6 for treatment and 6 for control group). First, guinea pigs were infected with *Mtb* H₃₇Rv suspension by intramuscular injection. Infection was followed by sacrificing one animal each week and performing histopathological analysis from the organs. Chemotherapy was started 3 weeks after infection. PLGA-pT820 compound (50 mg/kg bw) was suspended in 1 mL sterile water and administered orally twice a week. Control animals were administered of 1 mL sterile water with the same frequency. After 12 weeks of chemotherapy, animals were euthanized by ketamine (40 mg/kg bw) and dexmedetomidine (0.5 mg/kg bw).

To count the number of bacteria in the organs, a portion of lung, spleen, liver and kidney were resected and homogenized in Sula media. 1:1000 dilutions of the homogenates were plated onto Löwenstein-Jensen solid media and after 8 weeks of incubation CFU was enumerated. For histopathological analysis, lung, spleen, liver, kidney, inguinal lymph nodes and heart muscle of each animal were removed and fixed in 8% neutral buffered formalin for 24 h at room temperature. Tissue specimens were dehydrated in a series of ethanol and xylene baths and embedded in paraffin wax. Sections (3–4 μm) were stained with hematoxylin and eosin (HE.). For *in situ* visualization of the acid-fast bacilli Ziehl–Neelsen (ZN) staining method was applied on similarly pre-treated sections.

3. Results and discussion

Palmitoylated tuftsin derivative was used as a carrier for the TB820 compound. Chemical structure and homogeneity of the conjugate was proved by mass spectrometry ($M_{\text{mo}}(\text{calculated}) = 1362.8$; $M_{\text{mo}}(\text{found}) = 1362.8$), analytical RP-HPLC and amino acid analysis. Structure and mass spectra of the pT820 conjugate is given in Figure 1.

The pT820 conjugate was encapsulated into PLGA nanoparticles by nanoprecipitation method. The encapsulation efficacy was up to 83%. The drug content of the PLGA-pT820 nanoparticles was 20.2%.

3.1. *In vitro* antitubercular effect, cytotoxicity and hemolytic activity

Antitubercular effect of the compounds was measured against *Mtb* H₃₇Rv strain. The MIC value of the TB820 molecule was 1 μg/mL (4.1 μM), while the MIC value of the pT820 conjugate was 5 μg/mL (3.7 μM). From this result we can conclude that the chemical modification of the TB820 molecule did not influence its

Download English Version:

<https://daneshyari.com/en/article/2401493>

Download Persian Version:

<https://daneshyari.com/article/2401493>

[Daneshyari.com](https://daneshyari.com)